EUCTR2011-002029-24-IT进行中（未招募）不适用
MULTICENTER SECOND LINE STUDY OF AXITINIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PROGRESSED WITH SORAFENIB
IVERSITA' CAMPUS BIOMEDICO0 个研究点开始时间: 2012年9月27日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •? Histologically or cytologically proven HCC or alpha-fetoprotein level > 400 ng/ml together with hypervascular tumor and cirrhosis documented by CT scan or MRI. BCLC criteria 2000 ? HCC not amenable to curative treatment (resection, transplantation, percutaneous ablation) ? prior systemic treatment for HCC with sorafenib ? Presence of at least one dimensionally measurable target lesion with largest diameter >= 2 cm. ? World Health Organization (WHO) performance status <= 2 ? Life expectancy >= 12 weeks. ? Age >= 18 years. ? Child Pugh score A ? Adequate hematologic functions (neutrophil count = 1500 per cubic millimeter; platelet count = 75,000 per cubic millimetre; Hemoglobin = 9 g/dl) ? Adequate liver function (bilirubin = 1.5 the upper limit of normal; AST and ALT = 2.5 x upper limit of normal (ULN), unless there are liver metastases in which case AST and ALT = 5.0 x ULN) ? Adequate renal function (serum creatinine ?1.5 x ULN or calculated creatinine clearance = 60 mL/min) ? Urinary protein <2+ by urine dipstick. If dipstick is = 2+ then a 24-hour urine collection can be done and the patient may enter only if urinary protein is <2 g per 24 hours. ? Adequate coagulation function ? No evidence of pre-existing uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart. The baseline systolic blood pressure readings must be ?140 mm Hg, and the baseline diastolic blood pressure readings must be ?90 mm Hg. Patients whose hypertension is controlled by antihypertensive therapies are eligible ? Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment ? Written informed consent ? Minimum of 4 weeks since any local procedures (chemoembolizzation or termoablation) or completion of radiation ? Minimum of 4 weeks since completion of all prior systemic anticancer therapy ? written informed consent approval by the institutional review board at each institution
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 29
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •? Decompensated cirrhosis (Child-Pugh score > 7) ? Variceal bleeding during the previous 3 months ? Gastrointestinal abnormalities including: History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment, inability to take oral medication, requirement for intravenous alimentation, prior surgical procedures affecting absorption including total gastric resection, treatment for active peptic ulcer disease in the past 6 months, active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy, malabsorption syndromes. ? Thromboembolic event during the previous 6 months, except for portal vein neoplastic thrombosis ? Current or anticipated use of drugs known to be potent CYP3A4 inhibitors (ie, grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, erythromycin, telithromycin, clarithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir and delavirdine). ? Current use or anticipated need for treatment with drugs that are known CYP3A4 or CYP1A2 inducers (ie, carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, phenytoin, amobarbital, nevirapine, primidone, rifabutin, rifampin, and St. John’s wort). ? Requirement of anticoagulant therapy with oral vitamin K antagonists. Low-dose anticoagulants for maintenance of patency of central venous access devise or prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular weight heparin is allowed. ? Abnormal cardiac function with history of ischemic heart disease in the previous 6 months, uncontrolled hypertension, unstable angina, severe cardiac arrhythmia ? Any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry. ? Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness. ? Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol. ? Active seizure disorder or evidence of brain metastases, spinal cord compression, or carcinomatous meningitis. ? Previous or current malignancies at other sites ? Concomitant antitumor treatment including tamoxifen or somatostatin analogs. ? Unstable systemic diseases or active uncontrolled infections. ? Female patients who are pregnant or lactating, or men and women of reproductive potential not willing or not able to employ an effective method of birth control/contraception to prevent pregnancy during treatment and for 6 months after discontinuing study treatment The definition of effective contraception should be in agreement with local regulation and based on the judgment of the principal investigator or a designated associate. ? Major surgery less that 4 weeks or radiation less than 2 weeks of starting study drug. ? Serious or non-healing wound, ulcer, or bone fracture. ? Uncontrolled Hypertension ? Class III or IV heart failure as defined by the NYHA functional classification system. ? Patients with thyroid abnormality not in cure. ? Any condition which, in the judgement of the Investigator, would place the patient at undue risk or interfere with the results of the study. ? Other concurrent chemotherapy, immunotherapy, radiotherapy
研究者
相似试验
进行中（未招募）
1 期
Phase II study of axitinib intensification plus nivolumab compared to nivolumab alone after induction with nivolumab plus ipilimumab in mRCC patients without previous complete response (AxIn study)metastatic renal cell carcinoma (mRCC)MedDRA version: 21.1Level: PTClassification code: 10050513Term: Metastatic renal cell carcinoma Class: 100000004864CTIS2024-511397-70-00Consorzio Oncotech118
进行中（未招募）
1 期
RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXITINIB (AG-013736) WITH OR WITHOUT DOSE TITRATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMAMetastatic RCCMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2008-007786-23-CZPfizer Inc 235 East 42nd Street, New York, NY10017200
进行中（未招募）
不适用
RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXITINIB (AG-013736) WITH OR WITHOUT DOSE TITRATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMAMetastatic RCCMedDRA version: 14.1Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007786-23-DEPfizer Inc 235 East 42nd Street, New York, NY10017 US200
进行中（未招募）
1 期
A Phase II study of Axitinib as maintenance for patients with advanced colorectal carcinoma.Advanced colorectal carcinomaMedDRA version: 14.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002384-16-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)49
进行中（未招募）
不适用
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENALCELL CANCER: AXIS TRIAMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaRenal cell carcinomaEUCTR2008-001451-21-IEPfizer Inc.,235 East 42nd Street,New York,NY 10017540